CurrentCareSourcePolicy N/A

UTILIZATION MANAGEMENT MEDICAL POLICY

Prior authorization policy for medical-benefit coverage of Imaavy (nipocalimab) IV for treatment of generalized myasthenia gravis (gMG) in patients aged ≥12 years who are anti-AChR or anti-MuSK antibody positive. Defines initial and continuation approval criteria, dosing, prescriber requirements, disallowed concomitant therapies, and duration of approvals.

Policy Summary

PayerCareSource

PolicyUTILIZATION MANAGEMENT MEDICAL POLICY

Policy CodePolicy N/A

Change TypeReview date update (05/14/2025)

Effective Date

Next Review Date

Key ActionPrior Authorization is recommended for medical benefit coverage; document antibody-positive status, MGFA class II-IV, unresolved symptoms or derived benefit, and pyridostigmine exposure/intolerance as applicable.

SourceLink

POLICY UPDATE CHANGES

Document review dated 05/14/2025 (Review Date noted); policy references April 2025 prescribing information and 2025 pivotal trial publication.

1Covered Indication (gMG antibody-positive ≥12 yrs)

2Approval Durations (initial, continuation)

3Disallowed Concomitant Therapies

Coverage Summary

Prior authorization policy for medical-benefit coverage of Imaavy (nipocalimab) IV for treatment of generalized myasthenia gravis (gMG) in patients aged ≥ 12 years who are anti‑AChR or anti‑MuSK antibody positive. Defines initial and continuation approval criteria, dosing, prescriber requirements, disallowed concomitant therapies, and duration of approvals. Coverage stance: covered_with_criteria. Last review date: 2025-05-14 (Review Date).

Dosing Requirements

Covered dosing per FDA-approved regimen:

ALL of the following

Initial dose: 30 mg/kg administered once via intravenous infusion over at least 30 minutes
Maintenance dose: 15 mg/kg IV infusion starting 2 weeks after initial dose and every 2 weeks thereafter; maintenance infusion over at least 15 minutes
Requests for doses outside of established dosing will be considered on a case-by-case basis by clinician (Medical Director or Pharmacist)

Prescriber & Administrative Requirements

Prescriber and Administrative Requirements

Specialty and administrative conditions for approval:

ALL of the following

Approval requires Imaavy to be prescribed by or in consultation with a physician who specializes in the condition treated (e.g., neurologist)
Prior Authorization is recommended for medical benefit coverage of Imaavy
All approvals provided for the duration noted (months: 1 month = 30 days equivalence)

Prior Authorization

Prior authorization required

Prior Authorization is recommended for medical-benefit coverage. Authorization durations: initial therapy — approve for 6 months; continuation (patient currently receiving Imaavy) — approve for 1 year. Requests for off-label doses will be considered case-by-case by a clinician.

Documentation Required

Document antibody status and clinical benefit

Document the following: confirmed anti‑AChR or anti‑MuSK antibody–positive status; Myasthenia Gravis Foundation of America (MGFA) classification II–IV; evidence of unresolved symptoms of generalized myasthenia gravis or, for patients currently receiving Imaavy, documentation from the prescriber that the patient is continuing to derive benefit; and prior or current pyridostigmine exposure or documentation of inadequate efficacy, contraindication, or significant intolerance to pyridostigmine as applicable.

Confirmed anti‑AChR or anti‑MuSK antibody positive
MGFA class II–IV
Evidence of unresolved symptoms OR documentation of derived benefit on therapy
Prior/current pyridostigmine exposure or intolerance/contraindication or inadequate efficacy

Billing Rule

Specialist prescriber requirement

Imaavy must be prescribed by or in consultation with a physician who specializes in the condition treated (e.g., a neurologist).

Not Recommended / Exclusions

Not Recommended for Approval

Situations in which coverage is not recommended:

ANY of the following

Concomitant use with another neonatal Fc receptor blocker
Concomitant use with a complement inhibitor (e.g., eculizumab/Soliris and biosimilars)
Concomitant use with a rituximab product
Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria

Clinical Evidence

-1.45LS mean difference in MG-ADL (Weeks 22–24): Imaavy vs placebo

-2.81LS mean difference in QMG (Weeks 22–24): Imaavy vs placebo

16.2%Responder rate difference (≥2‑point MG-ADL improvement): Imaavy vs placebo

The Vivacity‑MG3 Phase III randomized, double‑blind, placebo‑controlled trial (n=196) demonstrated Imaavy produced greater improvement in MG‑ADL (LS mean change Weeks 22–24: -4.70 Imaavy vs -3.25 placebo; difference -1.45, P = 0.0024) and QMG (LS mean change -4.86 vs -2.05; difference -2.81, P = 0.00012). Responder rate (≥2‑point MG‑ADL improvement) was 69% for Imaavy vs 53% for placebo (difference 16.2%, P = 0.021). Pediatric use for patients ≥12 years is supported by adult efficacy data plus pharmacokinetic and safety bridging data per the label and available studies.

Background & Definitions

Imaavy (nipocalimab) is a neonatal Fc receptor blocker indicated for treatment of generalized myasthenia gravis in adults and pediatric patients ≥ 12 years who are anti‑AChR or anti‑MuSK antibody positive. Efficacy was established in the Vivacity‑MG3 Phase III trial in adults; pediatric indication is supported by adult trial data plus additional pharmacokinetic and safety bridging, and an ongoing pediatric Phase II/III open‑label study is evaluating ages 2 to <18 years. Dosing per FDA regimen: initial IV dose 30 mg/kg once, then maintenance 15 mg/kg IV starting 2 weeks after initial dose and every 2 weeks thereafter.

Term	Definition
MGFA	Myasthenia Gravis Foundation of America classification
MG-ADL	Myasthenia Gravis Activities of Daily Living score